The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 16 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.This study has 1 Data Set.

The National Survey of Substance Abuse Treatment Services (N-SSATS) is designed to collect information from all facilities in the United States, both public and private, that provide substance abuse treatment. N-SSATS provides the mechanism for quantifying the dynamic character and composition of the United States substance abuse treatment delivery system. The objectives of N-SSATS are to collect multipurpose data that can be used to assist the Substance Abuse and Mental Health Services Administration (SAMHSA) and state and local governments in assessing the nature and extent of services provided and in forecasting treatment resource requirements, to update SAMHSA's Inventory of Behavioral Health Services (I-BHS), to analyze general treatment services trends, and to generate the online Substance Abuse Treatment Facility Locator http://findtreatment.samhsa.gov, as well as the National Directory of Drug and Alcohol Abuse Treatment Programs.

Data are collected on topics including facility operation, services offered (assessment, testing, transitional, ancillary, and pharmacotherapies), detoxification, primary focus (substance abuse, mental health, both, general health, and other), Opioid Treatment Programs and medications dispensed/prescribed, counseling and therapeutic approaches, standard operating procedures, special programs/groups offered, languages in which treatment is provided, type of treatment provided (hospital inpatient, residential, outpatient), number of clients (by service, total, and under age 18), number of beds, types of payment accepted, sliding fee scale, and facility accreditation and licensure/certification.

This study has 1 Data Set.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug-related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 22 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.This study has 1 Data Set.

The Treatment Episode Data Set -- Admissions (TEDS-A) is a national census data system of annual admissions to substance abuse treatment facilities. TEDS-A provides annual data on the number and characteristics of persons admitted to public and private substance abuse treatment programs that receive public funding. The unit of analysis is a treatment admission. TEDS consists of data reported to state substance abuse agencies by the treatment programs, which in turn report it to SAMHSA.

A sister data system, called the Treatment Episode Data Set -- Discharges (TEDS-D), collects data on discharges from substance abuse treatment facilities. The first year of TEDS-A data is 1992, while the first year of TEDS-D is 2006.

TEDS variables that are required to be reported are called the "Minimum Data Set (MDS)", while those that are optional are called the "Supplemental Data Set (SuDS)".

Variables in the MDS include: information on service setting, number of prior treatments, primary source of referral, gender, race, ethnicity, education, employment status, substance(s) abused, route of administration, frequency of use, age at first use, and whether methadone was prescribed in treatment. Supplemental variables include: diagnosis codes, presence of psychiatric problems, living arrangements, source of income, health insurance, expected source of payment, pregnancy and veteran status, marital status, detailed not in labor force codes, detailed criminal justice referral codes, days waiting to enter treatment, and the number of arrests in the 30 days prior to admissions (starting in 2008).

Substances abused include alcohol, cocaine and crack, marijuana and hashish, heroin, nonprescription methadone, other opiates and synthetics, PCP, other hallucinogens, methamphetamine, other amphetamines, other stimulants, benzodiazepines, other non-benzodiazepine tranquilizers, barbiturates, other non-barbiturate sedatives or hypnotics, inhalants, over-the-counter medications, and other substances.

Created variables include total number of substances reported, intravenous drug use (IDU), and flags for any mention of specific substances.This study has 1 Data Set.

The Treatment Episode Data Set -- Admissions (TEDS-A) is a national census data system of annual admissions to substance abuse treatment facilities. TEDS-A provides annual data on the number and characteristics of persons admitted to public and private substance abuse treatment programs that receive public funding. The unit of analysis is a treatment admission. TEDS consists of data reported to state substance abuse agencies by the treatment programs, which in turn report it to SAMHSA.

A sister data system, called the Treatment Episode Data Set -- Discharges (TEDS-D), collects data on discharges from substance abuse treatment facilities. The first year of TEDS-A data is 1992, while the first year of TEDS-D is 2006.

TEDS variables that are required to be reported are called the "Minimum Data Set (MDS)", while those that are optional are called the "Supplemental Data Set (SuDS)".

Variables in the MDS include: information on service setting, number of prior treatments, primary source of referral, gender, race, ethnicity, education, employment status, substance(s) abused, route of administration, frequency of use, age at first use, and whether methadone was prescribed in treatment. Supplemental variables include: diagnosis codes, presence of psychiatric problems, living arrangements, source of income, health insurance, expected source of payment, pregnancy and veteran status, marital status, detailed not in labor force codes, detailed criminal justice referral codes, days waiting to enter treatment, and the number of arrests in the 30 days prior to admissions (starting in 2008).

Substances abused include alcohol, cocaine and crack, marijuana and hashish, heroin, nonprescription methadone, other opiates and synthetics, PCP, other hallucinogens, methamphetamine, other amphetamines, other stimulants, benzodiazepines, other non-benzodiazepine tranquilizers, barbiturates, other non-barbiturate sedatives or hypnotics, inhalants, over-the-counter medications, and other substances.

Created variables include total number of substances reported, intravenous drug use (IDU), and flags for any mention of specific substances.This study has 1 Data Set.

The National Survey of Substance Abuse Treatment Services (N-SSATS) is designed to collect information from all facilities in the United States, both public and private, that provide substance abuse treatment. Data are collected on topics including facility operation, services offered (assessment and pre-treatment, pharmacotherapies, testing, transitional, ancillary), detoxification, primary focus (substance abuse, mental health, both, general health, and other), hotline operation, Opioid Treatment Programs and medications dispensed/prescribed, counseling and therapeutic approaches, languages in which treatment is provided, type of treatment provided, number of clients (total and under age 18), number of beds, types of payment accepted, sliding fee scale, special programs offered, facility accreditation and licensure/certification, and managed care agreements. N-SSATS was titled the Uniform Facility Data Set (UFDS) in 1997 and 1998. Data from these years along with N-SSATS 2000 and N-SSATS 2002 to N-SSATS 2011 are included in this concatenated dataset.This study has 1 Data Set.

The National Survey of Substance Abuse Treatment Services (N-SSATS) is designed to collect information from all facilities in the United States, both public and private, that provide substance abuse treatment. N-SSATS provides the mechanism for quantifying the dynamic character and composition of the United States substance abuse treatment delivery system. The objectives of N-SSATS are to collect multipurpose data that can be used to assist the Substance Abuse and Mental Health Services Administration (SAMHSA) and state and local governments in assessing the nature and extent of services provided and in forecasting treatment resource requirements, update SAMHSA's Inventory of Substance Abuse Treatment Services (I-SATS), analyze general treatment services trends, and generate the National Directory of Drug and Alcohol Abuse Treatment Programs and its online equivalent, the Substance Abuse Treatment Facility Locator http://findtreatment.samhsa.gov.

Data are collected on topics including facility operation, services offered (assessment, substance abuse therapy and counseling, pharmacotherapies, testing, transitional, ancillary), primary focus (substance abuse, mental health, both, general health, other), hotline operation, Opioid Treatment Programs and medication dispensed/prescribed, languages in which treatment is provided, type of treatment provided, number of clients (total and under age 18), number of beds, types of payment accepted, sliding fee scale, special programs offered, facility accreditation and licensure/certification, and managed care agreements.This study has 1 Data Set.

The Drug Abuse Warning Network (DAWN) survey is designed to

capture data on emergency department (ED) episodes that are induced by

or related to the use of an illicit, prescription, or over-the-counter

drug. For purposes of this collection, a drug "episode" is an ED visit

that was induced by or related to the use of an illegal drug or the

nonmedical use of a legal drug for patients aged six years and

older. A drug "mention" refers to a substance that was mentioned

during a drug-related ED episode. Because up to four drugs can be

reported for each drug abuse episode, there are more mentions than

episodes in the data. Individual persons may also be included more

than once in the data. Within each facility participating in DAWN, a

designated reporter, usually a member of the emergency department or

medical records staff, was responsible for identifying drug-related

episodes and recording and submitting data on each case. An episode

report was submitted for each patient visiting a DAWN emergency

department whose presenting problem(s) was/were related to their own

drug use. DAWN produces estimates of drug-related emergency department

visits for 50 specific drugs, drug categories, or combinations of

drugs, including the following: acetaminophen, alcohol in combination

with other drugs, alprazolam, amitriptyline, amphetamines, aspirin,

cocaine, codeine, diazepam, diphenhydramine, fluoxetine,

heroin/morphine, inhalants/solvents/aerosols, LSD, lorazepam,

marijuana/hashish, methadone, methamphetamine, and PCP/PCP in

combination with other drugs. The use of alcohol alone is not

reported. The route of administration and form of drug used (e.g.,

powder, tablet, liquid) are included for each drug. Data collected for

DAWN also include drug use motive and total drug mentions in the

episode, as well as race, age, patient disposition, reason for ED

visit, and day of the week, quarter, and year of episode.This study has 1 Data Set.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.

DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug-related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.

The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 22 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.This study has 1 Data Set.

The Drug Abuse Warning Network (DAWN) survey is designed to

capture data on emergency department (ED) episodes that are induced by

or related to the use of an illicit, prescription, or over-the-counter

drug. For purposes of this collection, a drug "episode" is an ED visit

that was induced by or related to the use of an illegal drug or the

nonmedical use of a legal drug for patients aged six years and

older. A drug "mention" refers to a substance that was mentioned

during a drug-related ED episode. Because up to four drugs can be

reported for each drug abuse episode, there are more mentions than

episodes in the data. Individual persons may also be included more

than once in the data. Within each facility participating in DAWN, a

designated reporter, usually a member of the emergency department or

medical records staff, was responsible for identifying drug-related

episodes and recording and submitting data on each case. An episode

report was submitted for each patient visiting a DAWN emergency

department whose presenting problem(s) was/were related to their own

drug use. DAWN produces estimates of drug-related emergency department

visits for 50 specific drugs, drug categories, or combinations of

drugs, including the following: acetaminophen, alcohol in combination

with other drugs, alprazolam, amitriptyline, amphetamines, aspirin,

cocaine, codeine, diazepam, diphenhydramine, fluoxetine,

heroin/morphine, inhalants/solvents/aerosols, LSD, lorazepam,

marijuana/hashish, methadone, methamphetamine, and PCP/PCP in

combination with other drugs. The use of alcohol alone is not

reported. The route of administration and form of drug used (e.g.,

powder, tablet, liquid) are included for each drug. Data collected for

DAWN also include drug use motive and total drug mentions in the

episode, as well as race, age, patient disposition, reason for ED

visit, and day of the week, quarter, and year of episode.This study has 1 Data Set.